ArticleFrontiers in pediatrics2025
The diagnostic value of global longitudinal strain on doxorubicin-induced cardiotoxicity in pediatric cancer patients: a cross-sectional study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric Cardio-Oncology: From Gap in Evidence to Future Perspectives.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy is a critical modality in the treatment of pediatric cancer. However, the risk of adverse effects remains a significant challenge despite the considerable advancements in chemotherapy efficacy. Anthracyclines are a cornerstone in the treatment of various childhood cancers but are associated with a notable risk of cardiotoxicity. Early detection of cardiac dysfunction in pediatric cancer patients is vital to prevent progression to heart failure, with echocardiography being one of the primary modalities for such assessments. Speckle Tracking Echocardiography (STE) is a recommended method for the early detection of cardiotoxicity in adult cancer patients, although its application in the pediatric population remains limited. This study aims to assess the diagnostic value of global longitudinal strain (GLS) in detecting doxorubicin-induced cardiotoxicity in pediatric cancer patients and to examine its correlation with cumulative doxorubicin doses. Methods: This cross-sectional study involved 52 pediatric cancer patients at Dr. Hasan Sadikin General Hospital. We performed both conventional echocardiography and STE for those receiving doxorubicin as their chemotherapy regimen. STE evaluated the correlation between cumulative doxorubicin dose and left ventricular function. Receiver Operating Characteristic (ROC) and area under the curve (AUC) were performed to evaluate the predictive model of GLS in diagnosing cardiac dysfunction based on conventional methods. This analysis also measures the model of cumulative doxorubicin doses to predict reduced GLS percentages. Results: A total of 52 subjects (67.3% male, mean age 10.3 years) were included in this study. Conventional echocardiography detected systolic dysfunction in 21.2% and diastolic dysfunction in 23.1% of patients. GLS measurements identified ventricular dysfunction in 19.2% of subjects. Significant risk factors for cardiotoxicity were cancer type and nutritional status, with Conclusion: This study suggests that GLS derived from STE may help identify early alterations in left ventricular function in pediatric patients receiving doxorubicin. Although reduced GLS was associated with systolic and diastolic dysfunction, differences were modest and within physiological limits. These findings highlight the potential role of GLS in cardiac monitoring, though further research is needed to confirm its diagnostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.